How Can Patient Data be Used to Lower Drug Costs?



 
Ogurchak: The availability of patient data and some of the specificity we can capture as a specialty pharmacy—particularly as it relates to adherence measures and outcomes measures—really helps us view that patient’s journey overall and help us act proactively.
 
The more that we know about adherence, the more that we know about how well patients are responding or not, really gives us the ability to make sure patients maintain on therapy and not incur additional spend that might occur with nonadherence.

Most Popular

Related Articles

Achilles Alon, PharmD, RPh, Director of Specialty Pharmacy, Co-owner of ACE-Rx Specialty Pharmacy, discusses what drove him to join the world of specialty pharmacy and the most rewarding part of it.
Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, talks about the impact orphan drugs have had on the specialty pharmaceutical industry.
Peter L. Salgo, MD; Steven L. D’Amato, RPh, BSPharm; Arturo Loaiza-Bonilla, MD, MSEd, FACP; Noa Biran, MD; and Carl T. Henningson, MD, remark on the role of specialty pharmacies in dispensing oral oncolytics.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2017
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.